WeVote
Log In

Bill

Bill

SD 1222

An Act relative to specialty medications and patient safety

194th Legislature (2025-2026) Introduced by Jason Lewis

Massachusetts bill addressing specialty medication access and safety protocols, referred to Financial Services Committee for insurance and cost-management review.

House concurred
0
WeVote Research Nonpartisan
Bill Summary · SD 1222

Legislative bill overview

Bill SD 1222 appears to address specialty medications and patient safety mechanisms in Massachusetts. Based on the title and referral to the Financial Services Committee, it likely involves insurance coverage, cost management, or access protocols for high-cost specialty drugs. The bill has moved through initial procedural steps and is now under committee review.

Why is this important

Specialty medications—typically high-cost drugs for chronic or rare conditions—represent a growing share of pharmaceutical spending and create significant affordability challenges for patients. Policy decisions about how these medications are covered, priced, and distributed directly affect patient access to potentially life-saving treatments and household healthcare costs.

Potential points of contention

  • Cost and coverage mechanisms: Whether the bill implements prior authorization requirements, step therapy protocols, or cost-sharing limits that could either protect patients or create barriers to treatment
  • Insurance vs. patient burden: How costs are distributed between insurers, patients, and manufacturers—and whether protections favor insurance companies over patient access
  • Definition and scope: Which medications qualify as "specialty" and which patient populations or conditions are covered, potentially excluding some groups

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.